Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models.

Meehan TF, Conte N, Goldstein T, Inghirami G, Murakami MA, Brabetz S, Gu Z, Wiser JA, Dunn P, Begley DA, Krupke DM, Bertotti A, Bruna A, Brush MH, Byrne AT, Caldas C, Christie AL, Clark DA, Dowst H, Dry JR, Doroshow JH, Duchamp O, Evrard YA, Ferretti S, Frese KK, Goodwin NC, Greenawalt D, Haendel MA, Hermans E, Houghton PJ, Jonkers J, Kemper K, Khor TO, Lewis MT, Lloyd KCK, Mason J, Medico E, Neuhauser SB, Olson JM, Peeper DS, Rueda OM, Seong JK, Trusolino L, Vinolo E, Wechsler-Reya RJ, Weinstock DM, Welm A, Weroha SJ, Amant F, Pfister SM, Kool M, Parkinson H, Butte AJ, Bult CJ.

Cancer Res. 2017 Nov 1;77(21):e62-e66. doi: 10.1158/0008-5472.CAN-17-0582.

PMID:
29092942
2.

Pharmacodynamic analyses in a multi-laboratory network: lessons from the poly(ADP-ribose) assay.

Ferry-Galow KV, Ji J, Kinders RJ, Zhang Y, Czambel RK, Schmitz JC, Herzog J, Evrard YA, Parchment RE.

Semin Oncol. 2016 Aug;43(4):492-500. doi: 10.1053/j.seminoncol.2016.06.007. Epub 2016 Jun 15.

PMID:
27663481
3.

Promise and limits of the CellSearch platform for evaluating pharmacodynamics in circulating tumor cells.

Wang L, Balasubramanian P, Chen AP, Kummar S, Evrard YA, Kinders RJ.

Semin Oncol. 2016 Aug;43(4):464-75. doi: 10.1053/j.seminoncol.2016.06.004. Epub 2016 Jun 15. Review.

4.

Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays.

Srivastava AK, Hollingshead MG, Weiner J, Navas T, Evrard YA, Khin SA, Ji JJ, Zhang Y, Borgel S, Pfister TD, Kinders RJ, Bottaro DP, Linehan WM, Tomaszewski JE, Doroshow JH, Parchment RE.

Clin Cancer Res. 2016 Jul 15;22(14):3683-94. doi: 10.1158/1078-0432.CCR-15-2323. Epub 2016 Mar 21.

5.

Discovery of heterocyclic nonacetamide synaptic vesicle protein 2A (SV2A) ligands with single-digit nanomolar potency: opening avenues towards the first SV2A positron emission tomography (PET) ligands.

Mercier J, Archen L, Bollu V, Carré S, Evrard Y, Jnoff E, Kenda B, Lallemand B, Michel P, Montel F, Moureau F, Price N, Quesnel Y, Sauvage X, Valade A, Provins L.

ChemMedChem. 2014 Apr;9(4):693-8. doi: 10.1002/cmdc.201300482. Epub 2014 Jan 20.

PMID:
24446373
6.

Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissues.

Pfister TD, Hollingshead M, Kinders RJ, Zhang Y, Evrard YA, Ji J, Khin SA, Borgel S, Stotler H, Carter J, Divelbiss R, Kummar S, Pommier Y, Parchment RE, Tomaszewski JE, Doroshow JH.

PLoS One. 2012;7(12):e50494. doi: 10.1371/journal.pone.0050494. Epub 2012 Dec 28.

7.

Mediation of CTCF transcriptional insulation by DEAD-box RNA-binding protein p68 and steroid receptor RNA activator SRA.

Yao H, Brick K, Evrard Y, Xiao T, Camerini-Otero RD, Felsenfeld G.

Genes Dev. 2010 Nov 15;24(22):2543-55. doi: 10.1101/gad.1967810. Epub 2010 Oct 21.

8.

Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity.

Kinders RJ, Hollingshead M, Lawrence S, Ji J, Tabb B, Bonner WM, Pommier Y, Rubinstein L, Evrard YA, Parchment RE, Tomaszewski J, Doroshow JH; National Cancer Institute Phase 0 Clinical Trials Team.

Clin Cancer Res. 2010 Nov 15;16(22):5447-57. doi: 10.1158/1078-0432.CCR-09-3076. Epub 2010 Oct 5.

9.

Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells.

Wang LH, Pfister TD, Parchment RE, Kummar S, Rubinstein L, Evrard YA, Gutierrez ME, Murgo AJ, Tomaszewski JE, Doroshow JH, Kinders RJ.

Clin Cancer Res. 2010 Feb 1;16(3):1073-84. doi: 10.1158/1078-0432.CCR-09-2799. Epub 2010 Jan 26.

10.

Gcn5 and SAGA regulate shelterin protein turnover and telomere maintenance.

Atanassov BS, Evrard YA, Multani AS, Zhang Z, Tora L, Devys D, Chang S, Dent SY.

Mol Cell. 2009 Aug 14;35(3):352-64. doi: 10.1016/j.molcel.2009.06.015.

11.

Developmental potential of Gcn5(-/-) embryonic stem cells in vivo and in vitro.

Lin W, Srajer G, Evrard YA, Phan HM, Furuta Y, Dent SY.

Dev Dyn. 2007 Jun;236(6):1547-57.

12.

Loss of Gcn5 acetyltransferase activity leads to neural tube closure defects and exencephaly in mouse embryos.

Bu P, Evrard YA, Lozano G, Dent SY.

Mol Cell Biol. 2007 May;27(9):3405-16. Epub 2007 Feb 26.

13.

GCN5 and p300 share essential functions during early embryogenesis.

Phan HM, Xu AW, Coco C, Srajer G, Wyszomierski S, Evrard YA, Eckner R, Dent SY.

Dev Dyn. 2005 Aug;233(4):1337-47.

14.

Alterations in Ca2+-dependent and cAMP-dependent signaling pathways affect neurogenesis and melanogenesis of quail neural crest cells in vitro.

Evrard YA, Mohammad-Zadeh L, Holton B.

Dev Genes Evol. 2004 Apr;214(4):193-9. Epub 2004 Feb 26.

PMID:
14991404
15.

c-Myc transformation domain recruits the human STAGA complex and requires TRRAP and GCN5 acetylase activity for transcription activation.

Liu X, Tesfai J, Evrard YA, Dent SY, Martinez E.

J Biol Chem. 2003 May 30;278(22):20405-12. Epub 2003 Mar 26.

16.

Loss of Gcn5l2 leads to increased apoptosis and mesodermal defects during mouse development.

Xu W, Edmondson DG, Evrard YA, Wakamiya M, Behringer RR, Roth SY.

Nat Genet. 2000 Oct;26(2):229-32.

PMID:
11017084
17.

lunatic fringe is an essential mediator of somite segmentation and patterning.

Evrard YA, Lun Y, Aulehla A, Gan L, Johnson RL.

Nature. 1998 Jul 23;394(6691):377-81.

PMID:
9690473
18.

Effects of cell-free perfusion and almitrine bismesylate on the ultrastructure of type-I cell mitochondria in the cat carotid body.

Kennedy M, Giles S, O'Regan RG, Feely S, Evrard Y.

Adv Exp Med Biol. 1993;337:51-9. No abstract available.

PMID:
8109433
19.

The effects of almitrine on (3H)5HT and (125I) endothelin binding to central and peripheral receptors: an in vitro autoradiographic study in the cat.

Dashwood MR, McQueen DS, Sykes RM, Muddle JR, Daly MD, Evrard Y, Spyer KM.

Adv Exp Med Biol. 1993;337:17-23. No abstract available.

PMID:
8109397
20.

Effects of almitrine on the release of catecholamines from the rabbit carotid body in vitro.

Almaraz L, Rigual R, Obeso A, Evrard Y, Gonzalez C.

Br J Pharmacol. 1992 Jul;106(3):697-702.

21.

Ganglioglomerular nerves influence responsiveness of cat carotid body chemoreceptors to almitrine.

McQueen DS, Evrard Y, Gordon BH, Campbell DB.

J Auton Nerv Syst. 1989 Jun;27(1):57-66.

PMID:
2529305
22.

Recent data on the pharmacology of fenspiride.

Lonchampt M, Evrard Y, Duhault J.

Rhinol Suppl. 1988;4:59-66. No abstract available.

PMID:
2907676
23.

Inhibitory effect of almitrine on dopaminergic activity of rat carotid body.

Pequignot JM, Tavitian E, Boudet C, Evrard Y, Claustre J, Peyrin L.

J Appl Physiol (1985). 1987 Aug;63(2):746-51.

PMID:
3654437
24.

[Approach to the mechanism of action of almitrine dimesylate on peripheral receptors and the ventilation-perfusion ratio (VA/Q)].

Evrard Y.

Rev Med Interne. 1985;6 Spec No:53-8. Review. French. No abstract available.

PMID:
3010419
25.

[Almitrine bismesylate and ventilation-perfusion ratios].

Evrard Y.

Rev Mal Respir. 1985;2 Suppl 1:S17-22. French.

PMID:
2870542
26.

[Pharmacological properties of almitrine dimesylate. Effects on the ventilation-perfusion ratio].

Evrard Y.

Presse Med. 1984 Oct 4;13(34):2063-9. Review. French.

PMID:
6149533
27.

[New therapeutic indications for a dopamine antagonist, Piribedyl].

Schmitt H, Laubie M, Poignant JC, Krikorian A, Evrard Y, Freyria JL, Arnaud F.

Sem Hop. 1978 Mar;54(5-8):325-34. French.

PMID:
211628

Supplemental Content

Loading ...
Support Center